OBJECTIVE: Protein citrullination is an important posttranslational modification recognized by rheumatoid arthritis (RA)-specific autoantibodies. One of the citrullinating enzymes, peptidyl arginine deiminase type 4 (PAD-4), is genetically associated with development of RA in some populations, although the mechanism(s) mediating this effect are not yet clear. There have been descriptions of anti-PAD-4 autoantibodies in different rheumatic diseases. This study was undertaken to investigate whether anti-PAD-4 antibodies are specific to RA, are associated with disease phenotype or severity, and whether PAD-4 polymorphisms influence the anti-PAD-4 autoantibody response. METHODS: Sera from patients with established RA, patients with other rheumatic diseases, and healthy adults were assayed for anti-PAD-4 autoantibodies by immunoprecipitation of in vitro-translated PAD-4. The epitope(s) recognized by PAD-4 autoantibodies were mapped using various PAD-4 truncations. PAD-4 genotyping was performed on RA patients with the TaqMan assay. Joint erosions were scored from hand and foot radiographs using the Sharp/van der Heijde method. RESULTS: PAD-4 autoantibodies were found in 36-42% of RA patients, and were very infrequent in controls. Recognition by anti-PAD-4 autoantibodies required the 119 N-terminal amino acids, which encompass the 3 nonsynonymous polymorphisms associated with disease susceptibility. Strikingly, the anti-PAD-4 immune response was associated with the RA susceptibility haplotype of PADI4. Anti-PAD-4 antibodies were associated with more severe joint destruction in RA. CONCLUSION: Our findings indicate that anti-PAD-4 antibodies are specific markers of RA, independently associated with more severe disease, suggesting that an anti-PAD-4 immune response may be involved in pathways of joint damage in this disease. Polymorphisms in the PADI4 gene influence the immune response to the PAD-4 protein, potentially contributing to disease propagation.
OBJECTIVE: Protein citrullination is an important posttranslational modification recognized by rheumatoid arthritis (RA)-specific autoantibodies. One of the citrullinating enzymes, peptidyl arginine deiminase type 4 (PAD-4), is genetically associated with development of RA in some populations, although the mechanism(s) mediating this effect are not yet clear. There have been descriptions of anti-PAD-4 autoantibodies in different rheumatic diseases. This study was undertaken to investigate whether anti-PAD-4 antibodies are specific to RA, are associated with disease phenotype or severity, and whether PAD-4 polymorphisms influence the anti-PAD-4 autoantibody response. METHODS: Sera from patients with established RA, patients with other rheumatic diseases, and healthy adults were assayed for anti-PAD-4 autoantibodies by immunoprecipitation of in vitro-translated PAD-4. The epitope(s) recognized by PAD-4 autoantibodies were mapped using various PAD-4 truncations. PAD-4 genotyping was performed on RApatients with the TaqMan assay. Joint erosions were scored from hand and foot radiographs using the Sharp/van der Heijde method. RESULTS:PAD-4 autoantibodies were found in 36-42% of RApatients, and were very infrequent in controls. Recognition by anti-PAD-4 autoantibodies required the 119 N-terminal amino acids, which encompass the 3 nonsynonymous polymorphisms associated with disease susceptibility. Strikingly, the anti-PAD-4 immune response was associated with the RA susceptibility haplotype of PADI4. Anti-PAD-4 antibodies were associated with more severe joint destruction in RA. CONCLUSION: Our findings indicate that anti-PAD-4 antibodies are specific markers of RA, independently associated with more severe disease, suggesting that an anti-PAD-4 immune response may be involved in pathways of joint damage in this disease. Polymorphisms in the PADI4 gene influence the immune response to the PAD-4 protein, potentially contributing to disease propagation.
Authors: A Martinez; A Valdivia; D Pascual-Salcedo; J Ramón Lamas; M Fernández-Arquero; A Balsa; B Fernández-Gutiérrez; E G de la Concha; E Urcelay Journal: Rheumatology (Oxford) Date: 2005-07-05 Impact factor: 7.580
Authors: Mark C Genovese; Jean-Claude Becker; Michael Schiff; Michael Luggen; Yvonne Sherrer; Joel Kremer; Charles Birbara; Jane Box; Kannan Natarajan; Isaac Nuamah; Tracy Li; Richard Aranda; David T Hagerty; Maxime Dougados Journal: N Engl J Med Date: 2005-09-15 Impact factor: 91.245
Authors: K T Jørgensen; A Wiik; M Pedersen; C J Hedegaard; B F Vestergaard; R E Gislefoss; T K Kvien; J Wohlfahrt; K Bendtzen; M Frisch Journal: Ann Rheum Dis Date: 2007-07-20 Impact factor: 19.103
Authors: Annette H M van der Helm-van Mil; Kirsten N Verpoort; Ferdinand C Breedveld; René E M Toes; Tom W J Huizinga Journal: Arthritis Res Ther Date: 2005-06-14 Impact factor: 5.156
Authors: Berthold Hoppe; Thomas Häupl; Rudolf Gruber; Holger Kiesewetter; Gerd R Burmester; Abdulgabar Salama; Thomas Dörner Journal: Arthritis Res Ther Date: 2006-01-16 Impact factor: 5.156
Authors: Erika Darrah; Fang Yu; Laura C Cappelli; Antony Rosen; James R O'Dell; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2019-04-10 Impact factor: 10.995
Authors: Corey P Causey; Justin E Jones; Jessica L Slack; Daisuke Kamei; Larry E Jones; Venkataraman Subramanian; Bryan Knuckley; Pedram Ebrahimi; Alexander A Chumanevich; Yuan Luo; Hiroshi Hashimoto; Mamoru Sato; Lorne J Hofseth; Paul R Thompson Journal: J Med Chem Date: 2011-09-16 Impact factor: 7.446
Authors: Pei-Song Gao; Kenichi Shimizu; Audrey V Grant; Nicholas Rafaels; Lin-Fu Zhou; Sherry A Hudson; Satoshi Konno; Nives Zimmermann; Maria I Araujo; Eduardo V Ponte; Alvaro A Cruz; Masaharu Nishimura; Song-Nan Su; Nobuyuki Hizawa; Terry H Beaty; Rasika A Mathias; Marc E Rothenberg; Kathleen C Barnes; Bruce S Bochner Journal: Eur J Hum Genet Date: 2010-01-20 Impact factor: 4.246
Authors: Marian L Burr; Haris Naseem; Anne Hinks; Steve Eyre; Laura J Gibbons; John Bowes; Anthony G Wilson; James Maxwell; Ann W Morgan; Paul Emery; Sophia Steer; Lynne Hocking; David M Reid; Paul Wordsworth; Pille Harrison; Wendy Thomson; Jane Worthington; Anne Barton Journal: Ann Rheum Dis Date: 2009-05-25 Impact factor: 19.103